Group 1 - Spectral AI stock has seen significant gains, attributed to recent funding developments and positive investor sentiment [1][3] - The company received immediate, non-dilutive funding from BARDA, adding to the previously committed $54.9 million under an existing contract, which has a total potential value of up to $150 million [2] - Spectral AI will contribute an additional $9.7 million towards the development costs associated with advancements in their technology [2] Group 2 - The funding will support the development of the DeepView System, which is aimed at enhancing FDA clearance efforts and expediting Phase II initiatives, including total body surface area mapping [4] - DeepView is designed for use in emergency departments, trauma centers, and burn centers, facilitating faster, data-driven clinical treatment decisions in wound care [5] - As of Thursday morning, Spectral AI shares increased by 8.33%, reaching a price of $1.30 [7]
Spectral AI Stock Jumps After $31.7 Million Funding Award